LC
CAPR icon

Lindbrook Capital’s Capricor Therapeutics CAPR Stock Holding History

Lindbrook Capital’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$493 Buy
+52
New +$722 ﹤0.01% 2621

Other funds holding CAPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Lindbrook Capital's CAPR Position: Q1 2025 in Review

Lindbrook Capital opened a new position in Capricor Therapeutics (CAPR) in Q1 2025: 52 shares worth $493. The stake represents ﹤0.01% of the portfolio and ranks #2621 among its holdings.

120 funds tracked by Wall St. Rank hold CAPR as of Q1 2025.

  • Lindbrook Capital held 52 shares of Capricor Therapeutics worth $493 as of Q1 2025.
  • Capricor Therapeutics was a new Lindbrook Capital position in Q1 2025.
  • Capricor Therapeutics made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #2621 holding.
  • 120 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.